Catalyst Event
Johnson & Johnson (JNJ) · Other
From Akros U.S. Tech 100 Protective Allocation Monthly Index (A100PAM)
4/27/2026, 12:00:00 AM
Announced that the U.S. FDA approved a supplemental New Drug Application (sNDA) for CAPLYTA® (lumateperone) to be used for the prevention of relapse in adults with schizophrenia.
Korean Translation
미국 FDA가 성인 조현병 환자의 재발 방지를 위한 치료제 카플리타(CAPLYTA®, lumateperone)의 보충 신약 허가 신청(sNDA)을 승인했다고 발표함.
Related Recent Events
Cadence Design Systems Inc (CDNS) · Earnings Release
Q2 2026 earnings release scheduled for July 27, 2026. Medium importance is estimated as investors will monitor the impact of recent acquisitions on the updated guidance, scheduled.
7/27/2026, 12:00:00 AM
Netflix Inc (NFLX) · Earnings Release
Netflix is expected to announce its Q2 2026 financial results on 2026-07-16 based on past reporting schedules; low impact is estimated as this is a routine announcement expected.
7/16/2026, 12:00:00 AM
Honeywell International Inc (HON) · Trading Issue
The spin-off of the Honeywell Aerospace business is scheduled to be completed on June 29, 2026. This major corporate action will change share counts and is expected to have a high price impact, scheduled.
6/29/2026, 12:00:00 AM
QUALCOMM Inc. (QCOM) · Other
Qualcomm has scheduled an Investor Day for June 24, 2026, where it is expected to provide updates on its strategy and long-term outlook, scheduled. Low importance is estimated as such events typically result in price impacts of at least 1%.
6/24/2026, 12:00:00 AM
Automatic Data Processing Inc (ADP) · Other
Quarterly dividend of $1.70 per share, ex-dividend date scheduled for 2026-06-12; price impact of at least 1% expected.
6/12/2026, 12:00:00 AM
Adobe Inc (ADBE) · Earnings Release
Adobe's Q2 2026 earnings release is scheduled.
6/11/2026, 12:00:00 AM